Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease –
— CD20 靶向 GADLEN 證明了人類化小鼠和非人類靈長類動物中快速 B 細胞枯竭的概念的臨床前證明，旨在用於自身免疫性疾病的臨床發展 —
AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company's GADLEN platform.
德克薩斯州奧斯汀和北卡羅來納州達勒姆，2023 年 3 月 16 日（GLOBE NEWSWIRE）-沙特塔克實驗室有限公司（NASDAQ：STTK），率先開發雙功能融合蛋白作為治療癌症和自身免疫性疾病患者的新類生物醫學，今天在 2023 上宣布了美國癌症協會（AACR）的臨床前研究數據在佛羅里達州奧蘭多舉行的年度會議，來自該公司的 GADLEN 平台。
"We are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human Vγ9Vδ2 T cells to serially kill greater than 99% of human B cells in a humanized mouse model," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "These data led to the first study of a GADLEN compound in non-human primates, where once again treatment with a CD20-targeted GADLEN directed low frequencies of endogenous Vγ9Vδ2 T cells to eliminate CD20 positive B cells with a rapid kinetic. Importantly, the GADLEN compound was well tolerated in non-human primates up to the highest administered dose of 25 mg/kg, without evidence of cytokine release syndrome or other toxicities, potentially providing differentiation from CD3-directed T cell engagers. These data underlie our enthusiasm to advance a GADLEN product candidate into the clinic designed for the treatment of antibody-mediated autoimmune diseases."
Stltuck 首席執行官博士 Daylor Schreiber 博士表示：「我們很高興與大家分享臨床前資料，證明了以 CD20 為目標的 GADLEN 有效地引導少量人類 V9VΔ2 T 細胞，以連續殺死超過 99% 的人類 B 細胞。「這些數據導致了 GADLEN 化合物在非人類靈長類動物的第一項研究, 其中再次治療與 CD20 靶向的 GADLEN 內源性 V9VΔ2 T 細胞的低頻，以消除 CD20 陽性 B 細胞與快速動力學.重要的是，GADLEN 化合物在非人類靈長類動物中具有良好的耐受性，最高給藥劑量為 25 mg/kg，沒有細胞因子釋放綜合徵或其他毒性的證據，可能提供與 CD3 導向 T 細胞接合劑的分化。這些數據基於我們熱情地將 GADLEN 產品候選產品推進該診所，該診所旨在治療抗體介導的自身免疫性疾病。」
Details of the presentations are as follows:
簡報詳情如下：
Abstract title: Rapid Serial Killing of Target Cells by Vγ9Vδ2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1/3A1 Fusion Protein
摘要題目：V9V 快速連續殺死目標細胞δ用 CD20 指導性雜質丁氧胺 2A1/3A1 融合蛋白處理的氰化獼猴和人性化小鼠中的 2 T 細胞
Shattuck to present preclinical data highlighting the potential of a CD20-targeted GADLEN to direct Vγ9Vδ2 T cells to kill B cells in vivo in cynomolgus macaques and a humanized mouse model.
沙塔克將呈現臨床前數據，突出顯示以 CD20 為目標的 GADLEN 引導 V9VΔ2 T 細胞殺死 B 細胞的潛力 在体内 在球黴菌獼猴和人性化的小鼠模型。
Shattuck's bispecific GADLEN compound, which contains heterodimeric BTN2A1 and BTN3A1 extracellular domains fused via an inert Fc linker to an scFv domain targeting CD20 tumor-antigens, demonstrated an ability to rapidly deplete human and cynomolgus B cells in a dose-dependent manner.
沙塔克的雙特異性 GADLEN 化合物包含雜質 BTN2A1 和 BTN3A1 細胞外域通過惰性 Fc 鏈接器融合到靶向 CD20 腫瘤抗原的 SCFV 域，證明能夠以劑量依賴性的方式快速消耗人類和半黴菌 B 細胞。
Location: Orange County Convention Center, Orlando, Florida
Presenter: Dr. Anne Lai, Ph.D., Associate Director R&D, Shattuck Labs
Session: Immunomodulatory Agents and Interventions 1
Date/Time: Monday, Apr 17, 2023, 9:00 AM - 12:30 PM
Location: Section 23
Poster Board Number: 19
Abstract Presentation Number: 1815
位置: 奧蘭治縣會議中心, 奧蘭多, 佛羅里達
主持人： 黎安妮博士，沙塔克實驗室研發副總監博士
工作階段： 免疫調節劑及干預措施 1
日期/時間 二零二三年四月十七日（星期一）上午九時至下午十二時三十分
位置: 第二十三節
海報板編號: 19
摘要簡報編號： 1815
Additional meeting information can be found on the AACR website, The poster will be available under Posters on the Company's website shortly after the event
其他會議資訊可在 AACR 網站上找到，該海報將在活動結束後不久在公司網站上的海報下找到
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: .
關於沙塔克實驗室
Shattuck Labs, Inc.（納斯達克股票代碼：STTK）是一家臨床階段的生物技術公司，致力於開發雙功能融合蛋白作為一種新的生物製藥類，用於治療癌症和自身免疫性疾病患者。從 Shattuck 的專有激動劑重定向檢查點 ARC 衍生的化合物，平台同時抑制檢查點分子，並通過單一治療激活共同刺激分子。該公司的首席 SL-172154（Sirpα-FC-CD40L）計劃正在多個第一階段試驗中進行評估，該計劃旨在阻止 CD47 免疫檢查點並同時激發 CD40 通路。此外，該公司正在推進專有的 Gamma Delta T 細胞接合器 GADLEN 平台，該平台旨在將伽瑪三角 T 細胞與腫瘤抗原相結合，用於治療癌症患者。Shattuck 在德克薩斯州奧斯汀和北卡羅萊納州達勒姆均設有辦事處。欲了解更多信息，請訪問：。
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
本公司擬使用其網站的投資者關係部分作為披露重大非公開資料的手段，以及遵守 FD 規例下的披露責任。
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@Shattucklabs.com
投資者及媒體聯絡人：
康納·理查森
投資人關係副總裁
沙塔克實驗室公司
InvestorRelations@Shattucklabs.com
譯文內容由第三人軟體翻譯。